Perfusion pharmacokinetics modeling


Quibim's Dynamic Contrast Enhanced (DCE) PKM perfusion automatically extracts vascular-based imaging biomarkers to detect changes associated with increased tumor neoangiogenesis activity and aggressiveness. The Pharmacokinetic (PKM) model used in the app helps detect neoplasms and quantifies tumor neoangiogenesis to stage cancer aggressiveness. This suite supports the characterization of tumoral processes in the early detection, diagnosis, treatment response evaluation and follow-up of patients with cancer.
Product specifications Information source: Vendor
Last updated: Feb. 11, 2022
Product name Perfusion pharmacokinetics modeling
Company Quibim
Subspeciality Abdomen
Modality MR
Disease targeted Solid tumors, Prostate cancer, Rectal cancer, Endometrial cancer, Liver cancer
Key-features Ktrans, Fractional volume of extra vascular extracellular space, Suggested use of software (before, during or after study assessment), time constant for gadolinium reflux from the EES back into the vascular system
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), Need to draw ROI
Data characteristics
Population Patients under pharmaceutical treatment for an anomaly or tumor
Input MRI DSC-MR (Dynamic Susceptibility Contrast)
Input format
Output One-page structured report: parametric maps, histograms and statistics summary of the rate of gadolinium influx from plasma into the EES (ktrans), time constant for gadolinium reflux (kep) and volume fraction of the EES (ve)
Output format DICOM Secondary Capture / PDF
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically after drawing ROI
Processing time > 10 minutes
Certified, Class IIa , MDD
No or not yet
Market presence
On market since 01-2019
Distribution channels Alma HEALTH PLATFORM
Countries present (clinical, non-research use) 10
Paying clinical customers (institutes) 5+
Research/test users (institutes) 15+
Pricing model License
Based on Number of installations, Number of analyses
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Martí-Bonmatí L, Ramírez-Fuentes C, Alberich-Bayarri Á, Ruiz-Llorca C. State-of-the-art of bone marrow imaging in multiple myeloma. Curr Opin Oncol. 2015 Nov; 27(6): 540-50.

Sanz-Requena R, Prats-Montalbán JM, Martí-Bonmatí L, Alberich-Bayarri Á, García-Martí G, Pérez R, Ferrer A. Automatic individual arterial input functions calculated from PCA outperform manual and population-averaged approaches for the pharmacokinetic modeling of DCE-MR images. J Magn Reson Imaging. 2015 Aug; 42(2): 477-87.